Novel colostrum based composition with gut health applications - Licensing Opportunity for Teagasc for November 2017 front page preview

Novel colostrum based composition with gut health applications - Licensing Opportunity for Teagasc for November 2017

Bovine colostrum and its derived component, IgG have been shown to alter the gut cell surface by increasing the number of attachment sites for health promoting bacteria, leading to their increased colonisation in vitro. ...

pdf 140.3KB

Ensifer based transformation of plant cells - Licensing Opportunity for Teagasc on November 2017 front page preview

Ensifer based transformation of plant cells - Licensing Opportunity for Teagasc on November 2017

This involves a novel method of transforming plant and fungal cells, for a wide range of crops. The primary technique for the generation of genetically modified (‘biotech’) crops utilises Agrobacterium tumefaciens in a p...

pdf 246.3KB

Objective medication adherence calculator A tool to aid patient adherence and optimise drug dosage Licensing Opportunity for RCSI June 2017 front page preview

Objective medication adherence calculator A tool to aid patient adherence and optimise drug dosage Licensing Opportunity for RCSI June 2017

Assessing adherence to medication is an essential element in the ongoing treatment of patients with chronic disease as well as in the development and trialling of new drugs. The current standard methods of adherence asse...

pdf 379.5KB

PanaColl- A collagen-based scaffold for the delivery of antibiotics and enhancement of tissue regeneration Licensing Opportunity for RCSI June 2017 front page preview

PanaColl- A collagen-based scaffold for the delivery of antibiotics and enhancement of tissue regeneration Licensing Opportunity for RCSI June 2017

Osteomyelitis (OM) is an infection of bone caused by bacteria such as Staphylococcus Aureus (S. Aureus). The current gold standard treatment for chronic OM is debridement of the infected bone followed by administration o...

pdf 462.2KB

ChemoGel - A thermoresponsive hydrogel for interventional oncology applications Licensing Opportunity from RCSI June 2017 front page preview

ChemoGel - A thermoresponsive hydrogel for interventional oncology applications Licensing Opportunity from RCSI June 2017

Thermoresponsive hydrogels have attracted significant attention for drug delivery due to their ability to phase-transition from an injectable liquid at room temperatures to a solid gel at physiological temperatures. Howe...

pdf 507.4KB